We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMODX
RNS Number : 6474O
Omega Diagnostics Group PLC
21 May 2018
Omega Diagnostics Group PLC
("Omega" or "the Company" or the "Group")
VISITECT(R) CD4 development update
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update with its VISITECT(R) CD4 development programme.
Further to the announcement on 10 April 2018, the Company recently held a design review meeting for its VISITECT(R) CD4 test for identifying advanced HIV disease*. The Company confirms that results from feasibility testing show acceptable performance against design goals and accordingly, the Company has progressed into a formal optimisation phase within its design control programme.
Colin King, CEO of Omega commented: "I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications. This enhancement to our 350 test line is crucial in managing patients with advanced diseases and one that the NGO community are keen to see brought to the market. I look forward to making further announcements as we bring this product to market."
* defined as those patients with lower than 200 CD4+ T cells per microlitre of blood
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group Tel: 01259 763 030 PLC Colin King, Chief Executive www.omegadiagnostics.com Kieron Harbinson, Group Finance Director finnCap Ltd Tel: 020 7220 0500 Geoff Nash/James Thompson (Corporate Finance) Camille Gochez/ Abigail Wayne (Corporate Broking) Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCURSKRWRAVURR
(END) Dow Jones Newswires
May 21, 2018 02:00 ET (06:00 GMT)
1 Year Omega Diagnostics Chart |
1 Month Omega Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions